title: Analytic performance of immunoassays for drugs of abuse below established cutoff values.
abstract: BACKGROUND
  The analytic performance and accuracy of drug detection below Substance Abuse and Mental Health Services Administration (SAMHSA) cutoffs is not well known. In some patient populations, clinically significant concentrations of abused drugs in urine may not be detected when current SAMHSA cutoffs are used. Our objectives were to define the precision profiles of three immunoassay systems for drugs of abuse and to evaluate the accuracy of testing at concentrations at which the CV was <20%.
  
  
  METHODS
  Drug-free urine was supplemented with analytes to assess the precision in three commercial drugs-of-abuse immunoassay systems below the SAMHSA-dictated cutoffs for amphetamines, opiates, benzoylecgonine, phencyclidine, and cannabinoids. Consecutive urine samples with signals associated with a CV <20% by Emit immunoassay and below SAMHSA cutoffs were then subjected to confirmatory analysis.
  
  
  RESULTS
  The CV of all immunoassay systems tested remained <20% to drug concentrations well below SAMHSA cutoffs. The accuracy of urine drug-screening results between the SAMHSA-specified cutoffs and the precision-based cutoffs was less than accuracy for specimens above the SAMHSA cutoffs, but the use of the precision-based cutoff produced a 15.6% increase in the number of screen-positive specimens and a 7.8% increase in the detection of specimens that yielded positive results on confirmatory testing.
  
  
  CONCLUSIONS
  The precision of three commercial immunoassay systems for drugs-of-abuse screening is adequate to detect drugs below SAMHSA cutoffs. Knowledge of the positive predictive values of screening immunoassays at lower cutoff concentrations could enable efficient use of confirmatory testing resources and improved detection of illicit drug use.
authors.affiliation: Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Veronica I
authors.initials: VI
authors.lastname: Luzzi
authors.forename: Al N
authors.initials: AN
authors.lastname: Saunders
authors.forename: John W
authors.initials: JW
authors.lastname: Koenig
authors.forename: John
authors.initials: J
authors.lastname: Turk
authors.forename: Stanley F
authors.initials: SF
authors.lastname: Lo
authors.forename: Uttam C
authors.initials: UC
authors.lastname: Garg
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: Dietzen
mesh_terms: D003042:Cocaine / Q000031:analogs & derivatives* / Q000652:urine; D003913:Dextroamphetamine / Q000652:urine; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000652:urine; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007118:Immunoassay; D009020:Morphine / Q000652:urine; D009294:Narcotics / Q000652:urine; D010622:Phencyclidine / Q000652:urine; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D015813:Substance Abuse Detection / Q000379:methods*
chemical_list: D009294:Narcotics; C009411:delta(6)-tetrahydrocannabinol-7-oic acid; C005618:benzoylecgonine; D009020:Morphine; D013759:Dronabinol; D003042:Cocaine; D010622:Phencyclidine; D003913:Dextroamphetamine